Polycystic Ovary Syndrome: Comprehensive Management and Health Impacts

The 2017 document outlines Polycystic Ovary Syndrome (PCOS) as a common endocrine disorder among reproductive-aged women, particularly prevalent in overweight and obese women. It is characterized by menstrual irregularity, hyperandrogenism, and polycystic ovarian morphology, leading to various complications such as infertility, obesity, insulin resistance, and dyslipidemia. The disorder is highly heritable and associated with elevated Anti-Müllerian Hormone levels. Women with PCOS are at an increased risk for mental health issues, cardiovascular disease, and a 2.7-fold increased risk of endometrial cancer. Diagnosis typically follows the Rotterdam criteria, and management includes lifestyle interventions, contraceptives for menstrual irregularities, anti-androgens for hyperandrogenism, and fertility treatments like clomiphene citrate and letrozole, with metformin and recombinant FSH as second-line treatments. The document highlights the need for comprehensive management of PCOS due to its complex pathophysiology and significant health impacts.